Trinity Biotech plc (NASDAQ:TRIB) has a beta value of 1.66 and has seen 2,035,918 shares traded in the last trading session. The company, currently valued at $53.13 Million, closed the last trade at $2.21 per share which meant it lost -$0.25 on the day or -10.16% during that session. The TRIB stock price is -20.36% off its 52-week high price of $2.66 and 74.66% above the 52-week low of $0.56. If we look at the company’s 10-day average daily trading volume, we find that it stood at 1.17 Million shares traded. The 3-month trading volume is 1.02 Million shares.

The consensus among analysts is that Trinity Biotech plc (TRIB) is a Buy stock at the moment, with a recommendation rating of 0. None of the analysts rate the stock as a Sell, while none rate it as Overweight. None out of 1 have rated it as a Hold, with 1 advising it as a Buy. None have rated the stock as Underweight. The expected earnings per share for the stock is $0.

Trinity Biotech plc (NASDAQ:TRIB) trade information

Despite being -10.16% in the red today, the stock has traded in the green over the last five days, with the highest price hit on Thursday, Jun 25 when the TRIB stock price touched $2.60-1 or saw a rise of 15%. Year-to-date, Trinity Biotech plc shares have moved 113.86%, while the 5-day performance has seen it change 7.8%. Over the past 30 days, the shares of Trinity Biotech plc (NASDAQ:TRIB) have changed 35.58%. Short interest in the company has seen 611.49 Million shares shorted with days to cover at 599.5.

Wall Street analysts have a consensus price target for the stock at $4, which means that the shares’ value could jump 81% from current levels. The projected low price target is $4 while the price target rests at a high of $4. In that case, then, we find that the current price level is +81% off the targeted high while a plunge would see the stock lose 81% from current levels.

Trinity Biotech plc (TRIB) estimates and forecasts

1 analysts offering their estimates for the company have set an average revenue estimate of $21.18 Million for the current quarter. 1 have an estimated revenue figure of $24.5 Million for the next quarter concluding in June 01, 2020. Year-ago sales stood $22.03 Million and $22.5 Million respectively for this quarter and the next, and analysts expect sales will grow by -3.9% for the current quarter and 8.9% for the next.

If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -37.51% over the past 5 years. Earnings growth for 2020 is a modest +0% while over the next 5 years, the company’s earnings are expected to increase by 15%.